Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

Open access
Quinn, David I, Tangen, Catherine M, Hussain, Maha, Lara, Primo N, Goldkorn, Amir, Moinpour, Carol M, Garzotto, Mark G, Mack, Philip C, Carducci, Michael A, Monk, J Paul, Twardowski, Przemyslaw W, Van Veldhuizen, Peter J, Agarwal, Neeraj, Higano, Celestia S, Vogelzang, Nicholas J, Thompson, Ian M · 2013 · The Lancet Oncology

Abstract

Background Bone metastasis is a hallmark of advanced prostate cancer. The endothelin pathway has a mechanistic role in bone metastases. Atrasentan, an endothelin receptor antagonist, has reported activity in prostate cancer. We assessed the survival impact of atrasentan in castration resistant prostate cancer (CRPC) patients with bone metastases being treated with standard-of-care docetaxel. Methods Men with metastatic CRPC were stratified for progression type (PSA or radiologic), baseline pain, extra skeletal metastases and bisphosphonate use and randomised using double-blinded methodology on a 1:1 ratio to docetaxel with atrasentan or placebo for up to 12 cycles of 3 weeks and treated until progression or unacceptable toxicity. Non-progressing patients were permitted to continue atrasentan or placebo for up to 52 weeks. Co-primary endpoints were progression-free (PFS) and overall survival (OS) where 930 patients are needed to detect a 25% increase in median overall survival of 18 months with the addition of atrasentan (1-sided log-rank α=0.025, power 87%, 4 years accrual, 2.5 additional years of follow-up). Results 1038 patents were accrued. Treatment was halted in April 2011, after an independent data safety monitoring committee pre-planned futility interim analysis. There was no significant difference in OS (HR=1.04 (95% CI 0.90,1.19) p=0.64) or PFS (HR=1.02 (95% CI 0.89,1.16) p=0.81). There was no significant difference between arms for RECIST or PSA response, treatment related deaths or grade 3 or more toxicity. Although 370 patients continued on blinded study drug after cessation of docetaxel, atrasentan did not significantly prolong post-chemotherapy OS in this subset. Interpretation Atrasentan, when added to docetaxel, does not improve overall or progression-free survival in men with castration-resistant prostate cancer and bone metastases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(13)70294-8

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 161

Metadata

Authors
Quinn, D. I., Tangen, C. M., Hussain, M., Lara, P. N., Goldkorn, A., Moinpour, C. M., Garzotto, M. G., Mack, P. C., Carducci, M. A., Monk, J. P., Twardowski, P. W., Van Veldhuizen, P. J., Agarwal, N., Higano, C. S., Vogelzang, N. J., & Thompson, I. M.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2013-08
Volume
14
Issue
9
Pages
893-900
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2113046540
Cited by
161
References
9
FWCI
19.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(13)70294-8
The paper
Quinn, D. I., Tangen, C. M., Hussain, M., Lara, P. N., Goldkorn, A., Moinpour, C. M., Garzotto, M. G., Mack, P. C., Carducci, M. A., Monk, J. P., Twardowski, P. W., Van Veldhuizen, P. J., Agarwal, N., Higano, C. S., Vogelzang, N. J., & Thompson, I. M. (2013). Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(13)70294-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.